A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease.
Phase of Trial: Phase I
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Dexlansoprazole (Primary)
- Indications Gastro-oesophageal reflux
- Focus Pharmacokinetics
- 08 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 21 Feb 2009 New trial record